Insmed: Discounted for Margin and Pipeline Risk
Insmed trades at a discount because the market sees margin and pipeline risks, not proven value. ROIC at -11.6% means capital destruction. For a biotech, that’s a red flag. Only real margin progress and pipeline wins could change the story.
Published by AssetNext · 2026-06-13
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-06-10 | Profile and price weak | 36 | -56.5% | -12.1% |
| 2026-06-05 | Profile and price weak | 35 | -55.4% | -33.1% |
| 2026-05-22 | Profile and price weak | 44 | -49.7% | -27.2% |
| 2026-05-15 | Profile and price weak | 43 | -48.4% | -28.9% |
Break down INSM's structural position across all peer dimensions with the interactive app.